Key clinical point: Tocilizumab was associated with improved vision in some patients with juvenile idiopathic arthritis (JIA) and uveitis refractory to TNF inhibitors.

Major finding: In a phase II multicenter trial, 7 of 21 JIA patients with uveitis refractory to TNFi biologics had a two-step decrease in inflammation and 3 others achieved a one-step improvement.

Data Source: Prospective multicenter single-arm phase 2 study; 22 children were enrolled.

Disclosures: Dr. Ramanan reports multiple financial relationships with pharmaceutical companies but received no funding for this study.